Metyrapone, marketed under the brand name Metopirone, is an adrenal steroid synthesis inhibitor used primarily for the diagnostic evaluation of adrenal insufficiency. It works by inhibiting the 11-beta-hydroxylation reaction in the adrenal cortex, leading to reduced production of cortisol and corticosterone. The drug also stimulates the production of adrenocorticotropic hormone (ACTH) by removing the inhibitory feedback of cortisol.
In clinical practice, Metyrapone is used as part of diagnostic tests to assess adrenal function. It is especially valuable for evaluating patients with suspected adrenal insufficiency. It is administered orally in the form of soft gelatin capsules, typically in a dose of 30 mg/kg (maximum 3 grams), and it is evaluated through measuring 11-desoxycortisol and ACTH levels.
